Identification and Characterization of Germline Mutations in Indian Women with Cancer: A Tertiary Center Next-Generation Sequencing Study

Abstract

Introduction

Hereditary cancer syndromes account for 5 to 10% of all malignancies, with BRCA1/2 and mismatch repair (MMR) genes playing crucial roles in breast, ovarian, and endometrial cancers. However, the prevalence and spectrum of germline mutations in Indian women remain inadequately characterized.

Objective

The aim of the study was to determine the proportion of patients harboring pathogenic or likely pathogenic (P/LP) variants and compare the mutation frequencies across cancer subtypes to help provide evidence for genetic counseling, cascade screening, and development of population-specific variant annotation resources to enhance precision oncology in India.

Materials and Methods

We prospectively enrolled 244 histopathologically confirmed cancer patients (193 women and 51 men) meeting National Comprehensive Cancer Network criteria for germline testing (August 2022–June 2025). Genomic DNA from peripheral blood underwent targeted enrichment using the GALEAS HereditaryPlus 146-gene panel and next-generation sequencing on an Illumina NextSeq 2000 platform (mean depth ∼500×). Variants were bioinformatically processed, aligned to the GRCh38 reference genome, and classified according to the guidelines of the American College of Medical Genetics and Genomics.

Results

P/LP variants were identified in 55/193 women (28.5%) and 6/51 men (11.8%). Among women, the highest mutation rates were observed in endometrial (30.0%), ovarian (28.6%), and breast (28.0%) cancers. BRCA1 (10.9%) and BRCA2 (6.7%) mutations predominated, followed by MMR genes (MLH1, MSH2, MSH6; cumulative 4.7%). Triple-negative breast cancer exhibited the highest mutation burden (35.1%, p < 0.01). Variants of uncertain significance were detected in 8.8% of women (17/193), highlighting the need for population-specific annotation resources.

Conclusion

More than one-quarter of Indian women with major gynecological malignancies harbor actionable germline variants. Our findings underscore the importance of routine multigene panel testing, systematic cascade screening in at-risk relatives, and the development of India-specific variant databases to facilitate precision oncology.

Keywords

germline mutation - hereditary cancer - BRCA1/2 - mismatch repair genes - next-generation sequencing - Indian population

Patient Consent

Written consent has been taken from the patient.

Publikationsverlauf

Artikel online veröffentlicht:
20. Januar 2026

• References

• 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (03) 229-263
• 2 Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res 2022; 156 (4&5): 598-607
• 3 Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed July 19, 2025, https://gco.iarc.fr/
• 4 Mohan R, Prabhu PR, Geetha GMN, Thulaseedharan JV. Female-specific cancers—India in the global context: an evaluation using GLOBOCAN 2022 estimates. CEOG 2025; 52 (04) 26363
• 5 Report of National Cancer Registry Programme. 2020 . Accessed July 19, 2025, https://ncdirindia.org/All_Reports/Report_2020/default.aspx
• 6 Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene-environment interactions on cancer development. Int J Environ Res Public Health 2020; 17 (21) 8089
• 7 Kuchenbaecker KB, Hopper JL, Barnes DR. et al; BRCA1 and BRCA2 Cohort Consortium. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317 (23) 2402-2416
• 8 Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7 (12) 937-948
• 9 Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348 (10) 919-932
• 10 Singh J, Thota N, Singh S. et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat 2018; 170 (01) 189-196
• 11 Mittal A, Deo SVS, Gogia A. et al. Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India. Ecancermedicalscience 2022; 16: 1434
• 12 Malhotra H, Kowtal P, Mehra N. et al. Genetic counseling, testing, and management of HBOC in India: an expert consensus document from Indian Society of Medical and Pediatric Oncology. JCO Glob Oncol 2020; 6: 991-1008
• 13 Kansuttiviwat C, Lertwilaiwittaya P, Roothumnong E. et al. Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand. NPJ Genom Med 2024; 9 (01) 9
• 14 Castéra L, Harter V, Muller E. et al; French Exome Project Consortium. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med 2018; 20 (12) 1677-1686
• 15 Vietri MT, D'Elia G, Caliendo G. et al. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer. Med Oncol 2021; 38 (02) 13
• 16 Gianluca Tedaldi DA. Genetic predisposition to breast and ovarian cancer. Int J Mol Sci 2020; 21: 1128
• 17 Agarwal S, Melgandi W, Sonkar DR. et al. Epidemiological characteristics of endometrial cancer patients treated at a tertiary health center in National Capital Territory of India. J Cancer Res Ther 2023; 19 (02) 452-456
• 18 Wang J, Wang Y, Li Y, Li X. Trend and characteristics of endometrial cancer in Guangzhou from 2000 to 2020. Eur J Obstet Gynecol Reprod Biol 2025; 305: 381-386
• 19 John AO, Singh A, Yadav P. et al. The BRCA mutation spectrum among breast and ovarian cancers in India: highlighting the need to screen BRCA1 185delAG among South Indians. Eur J Hum Genet 2024; 32 (10) 1319-1326
• 20 Kadri MSN, Patel KM, Bhargava PA. et al. Mutational landscape for Indian hereditary breast and ovarian cancer cohort suggests need for identifying population specific genes and biomarkers for screening. Front Oncol 2021; 10: 568786
• 21 Chheda P, Pande S, Dama T. et al. Spectrum of germline BRCA mutations in hereditary breast and ovarian cancer syndrome in Indian population: a central reference laboratory experience. Cancer Res Stat Treat 2020; 3 (01) 32
• 22 Lila K, Bhanushali H, Chanekar M. et al. Mutation spectrum analysis of BRCA1/2 genes for hereditary breast and ovarian cancer in the Indian population. Asian Pac J Cancer Prev 2024; 25 (12) 4145-4151
• 23 Gogia A, SG N, Pramanik R. et al. Prevalence of BRCA1 and BRCA2 mutations in an unselected cohort of Indian women with breast cancer. JCO 2023; 41 (16_suppl): e13004-e13004
• 24 Hodgson A, Turashvili G. Pathology of hereditary breast and ovarian cancer. Front Oncol 2020; 10: 531790
• 25 Ponti G, De Angelis C, Ponti R. et al. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies. Crit Rev Clin Lab Sci 2023; 60 (08) 640-650
• 26 Meindl A, Hellebrand H, Wiek C. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42 (05) 410-414
• 27 Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N. et al. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med 2021; 19 (01) 108
• 28 Carvalho CM, Braga LDC, Silva LM, Chami AM, Silva Filho ALD. Germline mutations landscape in a cohort of the state of Minas Gerais, Brazil, in patients who underwent genetic counseling for gynecological and breast cancer. Rev Bras Ginecol Obstet 2023; 45 (02) 74-81
• 29 Ajaz S, Zaidi SeZ, Ali S, Siddiqa A, Memon MA. Germline mutation analysis in sporadic breast cancer cases with clinical correlations. Front Genet 2022; 13: 820610
• 30 Yang X, Leslie G, Doroszuk A. et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 2020; 38 (07) 674-685
• 31 Koppiker CB. Abstract P3–07–08: germline mutational profiling in Indian TNBCs. Cancer Res 2022; 82 (4_Supplement): P3 –07–08
• 32 Kulkarni SS, Nag S, Patra A. et al. Prevalence of germline mutations in women with breast and/or ovarian cancer in a tertiary care center in Pune, India. IJMIO 2023; 8: 65-71
• 33 de Oliveira Ferreira C, Carneiro VCG, Araujo Mariz C. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System. BMC Cancer 2024; 24 (01) 499
• 34 Rebbeck TR, Friebel TM, Friedman E. et al; EMBRACE, GEMO Study Collaborators, HEBON. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 2018; 39 (05) 593-620
• 35 Bharati R, Jenkins MA, Lindor NM. et al. Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer?. Gynecol Oncol 2014; 133 (02) 287-292
• 36 Burde KG, Nair IR, Keechilattu P, Rajanbabu A. Prevalence of mismatch repair gene defects by means of immuno-histochemistry staining for MMR proteins in endometrial cancer. J Obstet Gynecol India 2025; 75 (Suppl. 01) 135-145
• 37 Venetis K, Frascarelli C, Bielo LB. et al. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer 2025; 217: 115233